China Information Technology, Inc.: Exhibit 4.1 - Filed by newsfilecorp.com






STANDSTILL AND WARRANT EXTENSION AGREEMENT 
(NO.
B[•]) 

THIS STANDSTILL AND WARRANT EXTENSION AGREEMENT is dated as of
September 23, 2015 (this “Agreement”), by and between CHINA INFORMATION
TECHNOLOGY, INC., a company incorporated under the laws of the British Virgin
Islands (the “Company”), and the Holder set forth on the signature page
hereto (the “Holder”). 

R E C I T A L
S 

A. The Company and the Holder are parties to that certain
Securities Purchase Agreement dated as of May 20, 2015 (the “Securities
Purchase Agreement”), by and among the Company and the investors party
thereto. 

B. At the Closing of the transactions contemplated by
Securities Purchase Agreement, the Company issued the Securities to the Holder
pursuant to an effective shelf registration statement on Form F-3 (Registration
Number 333-196755), including, among others, a Series B Warrant (the “Series
B Warrant”) to purchase an aggregate number of Ordinary Shares as set forth
therein (subject to adjustment as provided therein). Unless otherwise indicated,
all capitalized terms used and not otherwise defined herein have the respective
meanings ascribed to them in the Securities Purchase Agreement or the Series B
Warrant, as applicable. 

C. At the request of the Company, the Holder has agreed not to
exercise the Series B Warrant during the period set forth below in exchange for
an extension of the Expiration Date and the other terms and conditions set forth
below. 

A G R E E M E
N T 

NOW, THEREFORE, in consideration of the foregoing and the
mutual covenants, conditions and provisions contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereby agree as follows: 

1. Warrant Standstill. Subject to the terms and
conditions set forth herein and provided that with respect to any currently
outstanding and previously delivered Exercise Notices of the Holder (the
“Existing Notices”), the Company promptly delivers to the Holder the
number of Ordinary Shares the Holder is entitled (including, if applicable,
accounting for adjustments made for an Alternate Cashless Exercise) based on an
initial exercise of up to an aggregate maximum of 10,000 Warrant Shares (the
“Maximum Issuable Number”), regardless of the total number of Warrant
Shares originally exercised in such Existing Notices (the “Exercise Share
Delivery”), the Holder agrees that it shall not, and shall not be permitted
to, exercise the Series B Warrant, in whole or in part, for a period of three
(3) months from the date hereof (the “Suspension Period”); provided,
however, that upon the occurrence of (A) on any single Trading Date, the
Price Trigger (as defined below) and the Volume Trigger (as defined below), (B)
the Going Private Trigger (as defined below) or (C) the Company issues any
Ordinary Shares in respect of any exercise of another Series B Warrant (either
in respect of an Exercise Notice that has been previously delivered, but has not
been satisfied prior to the date hereof, or an Exercise Notice that is delivered
subsequent to the date hereof) to any other Holder 




who has not executed an agreement substantially identical in
form to this Agreement (a “Series B Exercise”) prior to expiration of the
Suspension Period, the Suspension Period shall be automatically and immediately
terminated and the Holder shall be permitted to exercise the Series B Warrant on
the Trading Day immediately following the applicable trigger date. For purposes
hereof, the “Price Trigger” shall mean the Trading Day during the
Suspension Period that (i) the quotient of (A) the sum of the VWAP of the
Ordinary Shares for each Trading Day of the five (5) lowest Trading Days during
any twelve (12) consecutive Trading Day period, divided by (B) five (5), is
greater than $3.00 (as adjusted for share splits, share distributions,
recapitalizations or similar events). For purposes hereof, the “Volume
Trigger” shall mean the Trading Day during the Suspension Period that (ii)
the quotient of (A) the sum of the trading volume of the Ordinary Shares for
each Trading Day of the five (5) highest volume Trading Days during any twelve
(12) consecutive Trading Day period, divided by (B) five (5) is greater than
300,000 Ordinary Shares (as adjusted for share splits, share distributions,
recapitalizations or similar events). For purposes hereof, the “Going Private
Trigger” means that the Company’s Board of Directors shall approve any
“going private” proposal submitted to the Company or its shareholders. The
Company shall within one (1) Trading Day inform the Holder in the event of (i)
the issuance and delivery of Ordinary Shares pursuant to any Exercise Notice in
excess of the Maximum Issuable Number or (ii) any Series B Exercise, each by any
other holder of a Series B Warrant during the Suspension Period. In the event
that the Company does not so inform the Holder of any such exercises, the
Expiration Date of the Holder’s Series B Warrant shall immediately, and without
any action by the Holder or the Company, be extended by an additional one (1)
year (the “Warrant Extension Period”). 

2. Extension of Expiration Date. Section 17(r) of the
Series B Warrant is hereby amended and restated in its entirety as follows: 

(r) “Expiration Date” means March 15, 2016, plus the
Warrant Extension Period, if any, or, if such date falls on a day other than a
Business Day or on which trading does not take place on the Principal Market (a
“Holiday”), the next date that is not a Holiday; provided, that
for each Business Day that the Company cannot or does not honor any Exercise
Notice (beyond the Share Delivery Date), the Expiration Date shall be extended
by one Business Day. 

3. Existing Notices. The exercise and issuance of all
Existing Notices shall be calculated based on the original exercise date of such
Existing Notices and, if more than one Existing Notice has been previously
delivered, they shall be processed in the order they were delivered to the
Company until the Maximum Issuable Number is met. Once the Company has issued
and delivered to the Holder the number of Ordinary Shares corresponding to the
Maximum Issuable Number, any remaining number of Warrant Shares under the
Existing Notices not exercised shall be voided. 

4. Confirmation; Full Force and Effect. The amendment
set forth in Section 2 amends the Series B Warrant on and as of the date hereof,
and the Series B Warrant shall remain in full force and effect, as amended
thereby, from and after the date hereof in accordance with its terms. The
Company hereby ratifies, approves and affirms in all respects each of the
Securities Purchase Agreement and the Series B Warrants (as amended) and the
other Transaction 

2 




Documents, the terms and other provisions hereof and thereof
and the obligations hereunder and thereunder. 

5. Representations and Warranties. To induce the Holders
to enter into this Agreement, the Company hereby represents and warrants to the
Holder that: 

(a) Due Authorization and Execution. The execution,
delivery and performance of this Agreement have been duly authorized by all
requisite corporate authority or other action on the part of the Company, this
Agreement has been duly executed and delivered by the Company, and this
Agreement constitutes the legal, valid and binding obligations of the Company,
enforceable against the Company in accordance with its terms; 

(b) No Material Adverse Effect. No event, liability,
development or circumstance has occurred or exists, or is reasonably expected to
exist or occur with respect to the Company, any of its Subsidiaries or any of
their respective businesses, properties, liabilities, prospects, operations
(including results thereof) or condition (financial or otherwise), that (i)
would be required to be disclosed by the Company under applicable securities
laws on a registration statement on Form F-3 filed with the SEC relating to an
issuance and sale by the Company of its Ordinary Shares and which has not been
publicly announced, or (ii) would reasonably be expected to have a Material
Adverse Effect; and 

(c) No Defense, Offset or Counterclaim. No events have
taken place and no circumstances exist at the date hereof which would give the
Company a basis to assert a defense, offset or counterclaim to any claim of any
Holder with respect to the obligations of the Company. 

6. Waiver of Claims. Subject to the timely delivery of
the Exercise Share Delivery, the Holder, by signing below, hereby waives and
releases the Company and their respective directors, officers, employees,
attorneys, affiliates and subsidiaries from any and all claims, offsets,
defenses and counterclaims (including, without limitation, any rights, claims,
offsets or penalties in connection with a prior Delivery Failure pursuant to
Section 1(c) of the Series B Warrant) of which the Holder is actually aware that
currently exists, such waiver and release being with full knowledge and
understanding of the circumstances and effect thereof and after having consulted
legal counsel with respect thereto.

7. Release. 

(a) Company Release. In consideration of the agreement
of the Holder contained herein and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the Company, on
behalf of itself and its successors, assigns, and other legal representatives,
hereby absolutely, unconditionally and irrevocably releases, remises and forever
discharges the Holder, and its successors and assigns, and its present and
former shareholders, partners, members, managers, consultants, affiliates,
subsidiaries, divisions, predecessors, directors, officers, attorneys,
employees, agents and other representatives, and all persons acting by, through,
under or in concert with any of them (each Holder and all such other Persons
being hereinafter referred to collectively as the “Releasees” and individually
as a “Releasee”) of and from all demands, actions, causes of action, suits,
covenants, contracts, 

3 




controversies, agreements, promises, sums of money, accounts,
bills, reckonings, damages and any and all other claims, counterclaims,
defenses, recoupment, rights of setoff, demands and liabilities whatsoever
(individually, a “Claim” and collectively, “Claims”) of every name and nature,
known or unknown, contingent or mature, suspected or unsuspected, both at law
and in equity, which the Company or any of its respective successors, assigns,
or other legal representatives may now or hereafter own, hold, have or claim to
have against the Releasees or any of them for, upon, or by reason of any
circumstance, action, cause or thing whatsoever which arises at any time on or
prior to the day and date of this Agreement, including, without limitation, for
or on account of, or in relation to, or in any way in connection with the
Securities Purchase Agreement, or any of the other Transaction Documents or
transactions thereunder or related thereto. 

(b) Full and Complete Defense. The Company understands,
acknowledges and agrees that the release set forth above may be pleaded as a
full and complete defense and may be used as a basis for an injunction against
any action, suit or other proceeding which may be instituted, prosecuted or
attempted in breach of the provisions of such release. 

(c) Release Absolute and Unconditional. The Company
agrees that no fact, event, circumstance, evidence or transaction which could
now be asserted or which may hereafter be discovered shall affect in any manner
the final, absolute and unconditional nature of the release set forth above.


(d) No Reliance. In entering into this Agreement, the
Company has consulted with, and has been represented by, legal counsel and
expressly disclaims any reliance on any representations, acts or omissions by
any of the Releasees and hereby agrees and acknowledges that the validity and
effectiveness of the release set forth above does not depend in any way on any
such representations, acts and/or omissions or the accuracy, completeness or
validity hereof. The provisions of this Section 7 shall survive the termination
of this Agreement and the other Transaction Documents. 

8. Disclosure of Transaction. The Company shall, on or
before 8:30 a.m., New York City Time, on the first business day after the date
that it enters into this Agreement, issue a press release and/or Report on Form
6-K (collectively, the “Press Release”) disclosing all material terms of
the transactions contemplated hereby and thereby. From and after the issuance of
the Press Release, the Holder shall not be in possession of any material,
nonpublic information received from the Company or any of its respective
officers, directors, employees or agents, that is not disclosed in the Press
Release. The Company shall not, and shall cause its officers, directors,
employees and agents, not to, provide the Holder with any material, nonpublic
information regarding the Company from and after the filing of the Press Release
without the express written consent of the Holder. The Company shall not
disclose the name of the Holder in any filing, announcement, release or
otherwise, unless such disclosure is required by law or regulation. 

9. Most Favored Nation. The Company hereby represents
and warrants as of the date hereof and covenants and agrees from and after the
date hereof that none of the terms offered to any other Holder of the Series B
Warrants with respect to any amendment, settlement or waiver (each a
“Settlement Document”) relating to the terms, conditions and transactions


4 




contemplated hereby, is or will be more favorable to such
Person than those of the Holder and this Agreement shall be, at the election of
the Holder, without any further action by the Holder or the Company, deemed
amended and modified in an economically and legally equivalent manner such that
the Holder shall receive the benefit of the more favorable terms contained in
such Settlement Document, including, without limitation, any provision in any
Settlement Document for the right to receive a number of Ordinary Shares in
respect of any exercise of another Series B Warrant (either in respect of an
Exercise Notice that has been previously delivered, but has not been satisfied
prior to the date hereof, or an Exercise Notice that is delivered subsequent to
the date hereof) in excess of the Maximum Issuable Number. Notwithstanding the
foregoing, the Company agrees, at its expense, to take such other actions (such
as entering into amendments to the Transaction Documents) as the Holder may
reasonably request to further effectuate the foregoing. 

10. Miscellaneous Provisions. 

(a) Entire Agreement; Successors and Assigns. This
Agreement constitutes the entire understanding and agreement between the parties
with respect to the subject matter hereof, and supersedes any and all other
prior oral and written, and all contemporaneous oral, agreements, negotiations,
discussions and understandings with respect thereto. This Agreement shall inure
to the benefit of, and be binding upon, the parties and their respective
successors and permitted assigns. 

(b) Trial by Jury; Governing Law; Jurisdiction;
Severability. TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE HOLDER AND THE
SELLER HEREBY WAIVE TRIAL BY JURY IN ANY ACTION BROUGHT ON OR WITH RESPECT TO
THIS AGREEMENT. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE
WITH THE INTERNAL SUBSTANTIVE LAWS OF THE STATE OF NEW YORK WITHOUT REFERENCE TO
THE RULES THEREOF RELATING TO CONFLICTS OF LAW OTHER THAN SECTION 5-1401 OF THE
GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, AND THE OBLIGATIONS, RIGHTS
AND REMEDIES OF THE PARTIES HEREUNDER SHALL BE DETERMINED IN ACCORDANCE WITH
SUCH LAWS. To the extent permitted by applicable Law, the parties hereto hereby
submit to the non-exclusive jurisdiction of the federal and state courts of
competent jurisdiction in the Borough of Manhattan in The City of New York in
any suit or proceeding arising out of or relating to this Agreement or the
transactions contemplated hereby. Any provision of this Agreement that is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof, and any such prohibition or
unenforceability in any jurisdiction shall (to the full extent permitted by Law)
not invalidate or render unenforceable such provision in any other jurisdiction.


(c) Headings. The headings of the Sections of this
Agreement have been inserted for convenience of reference only, are not to be
considered a part hereof and shall in no way modify or restrict any of the terms
or provisions hereof. 

(d) Counterparts. This Agreement may be executed in any
number of counterparts, each of which shall be deemed to be an original, but all
such counterparts shall 

5 




together constitute one and the same Agreement. Any counterpart
may be executed by facsimile or other electronic transmission, and such
facsimile or other electronic transmission shall be deemed an original. 

[Signature Page Follows] 

6 




IN WITNESS WHEREOF, the parties have caused this Agreement to
be executed and delivered by their duly authorized representatives as of the
date first written above. 

COMPANY 

CHINA INFORMATION TECHNOLOGY,

INC., a British Virgin Islands company 


	By: 	
	 	Name: 
	 	Title: 
	 	  
	 	  
	 	HOLDER 
	 	  
	 	  
	 	  
	 	  
	By: 	
	 	Name: 
	 	Title: 



[Signature Page to Standstill and Warrant Extension Agreement]